Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis

Although the anticancer effects of progesterone therapy for patients with endometrial carcinoma are widely acknowledged, a detailed assessment of the resultant morphologic alterations in tumor tissue kinetics has hitherto been lacking.

[1]  M. Saegusa,et al.  Down‐regulation of bcl‐2 expression is closely related to squamous differentiation and progesterone therapy in endometrial carcinomas , 1997, The Journal of pathology.

[2]  Q. Gao,et al.  Progesterone induces apoptosis and up‐regulation of p53 expression in human ovarian carcinoma cell lines , 1997, Cancer.

[3]  F. Montz,et al.  Progestin alone as primary treatment of endometrial carcinoma in premenopausal women , 1997, Cancer.

[4]  M. Saegusa,et al.  Bcl‐2 EXPRESSION IS CORRELATED WITH A LOW APOPTOTIC INDEX AND ASSOCIATED WITH PROGESTERONE RECEPTOR IMMUNOREACTIVITY IN ENDOMETRIAL CARCINOMAS , 1996, The Journal of pathology.

[5]  M. Saegusa,et al.  Correlation of apoptosis with tumour cell differentiation, progression, and HPV infection in cervical carcinoma. , 1996, Journal of clinical pathology.

[6]  C. Cohen,et al.  Endometrial cancer. Management of high risk and recurrence including the tamoxifen controversy , 1995, Cancer.

[7]  M. Saegusa,et al.  Apoptosis in Gastric Carcinomas and Its Association with Cell Proliferation and Differentiation , 1995, Japanese journal of cancer research : Gann.

[8]  T. Arai,et al.  Role of apoptosis in modulation of the growth of human colorectal tubular and villous adenomas , 1995, The Journal of pathology.

[9]  G. Núñez,et al.  Regulation and function of Bcl-2 during differentiation-induced cell death in HL-60 promyelocytic cells. , 1995, The American journal of pathology.

[10]  J. Crawford,et al.  Ultrastructural localization of a fluorinated bile salt in hepatocytes. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[11]  C. Winterford,et al.  Apoptosis. Its significance in cancer and cancer Therapy , 1994, Cancer.

[12]  S. Thorpe,et al.  Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: Correlations with stage and other clinicopathologic features , 1993, American journal of obstetrics and gynecology.

[13]  J. Isaacs,et al.  Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. , 1992, Cancer research.

[14]  G. Sutton,et al.  Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. , 1988, American journal of obstetrics and gynecology.

[15]  L. Gerschenson,et al.  Evidence for soluble factors regulating cell death and cell proliferation in primary cultures of rabbit endometrial cells grown on collagen. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[16]  K. Mccarty,et al.  Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. , 1985, American journal of obstetrics and gynecology.

[17]  L. Gerschenson,et al.  Estrogen and progesterone regulation of proliferation, migration, and loss in different target cells of rabbit uterine epithelium. , 1984, Endocrinology.

[18]  R. Lieberman,et al.  Effect of progesterone and 17 beta-estradiol on the production of uteroglobin by cultured rabbit uterine epithelial cells. , 1983, Endocrinology.

[19]  R. Brenner,et al.  Hormonal control of apoptosis in hamster uterine luminal epithelium. , 1979, The American journal of anatomy.

[20]  L. Gerschenson,et al.  Hormonal regulation of proliferation in two populations of rabbit endometrial cells in culture. , 1979, Life sciences.

[21]  E. C. Reifenstein.  The treatment of advanced endometrial cancer with hydroxyprogesterone caproate. , 1974, Gynecologic oncology.

[22]  A. Currie,et al.  Adrenocortical cell deletion: The role of ACTH , 1973, The Journal of pathology.

[23]  J. Kerr,et al.  Deletion of cells by apoptosis during castration-induced involution of the rat prostate , 1973, Virchows Archiv. B, Cell pathology.

[24]  R. M. Kelley,et al.  Progestational agents in the treatment of carcinoma of the endometrium. , 1961, The New England journal of medicine.

[25]  R. Kistner.  Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium , 1959, Cancer.

[26]  John Calvin Reed,et al.  Immunohistochemical analysis of the Bcl-2 oncoprotein in human neuroblastomas. Comparisons with tumor cell differentiation and N-Myc protein. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[27]  O. F. Chepick.  Morphological aspects of the hormone-induced pathomorphosis of endometrial carcinoma. , 1993, European journal of gynaecological oncology.

[28]  Chepick Of.  Morphological aspects of the hormone-induced pathomorphosis of endometrial carcinoma. , 1993 .

[29]  D. Herbold,et al.  The significance of squamous differentiation in endometrial carcinoma , 1988 .

[30]  N. Davidson,et al.  Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. , 1991, Cancer research.

[31]  N. W. Elton.  Morphologic Variations in Adenocarcinoma of the Fundus of the Uterus, with Reference to Secretory Activity and Clinical Interpretations , 1942 .